Home › Entities › academia › Dynamic contrast-enhanced MRI to predict response to vinorelbine–cisplatin alone or with rh-endostatin in patients with non-small cell lung cancer and bone metastases: a randomised, double-blind, placebo-controlled trial

Dynamic contrast-enhanced MRI to predict response to vinorelbine–cisplatin alone or with rh-endostatin in patients with non-small cell lung cancer and bone metastases: a randomised, double-blind, placebo-controlled trial

Research article (The Lancet, 2016) · cited 10× · AI/ML
academia openalex:W2545338794
Press Enter · cited answer in seconds

Dynamic contrast-enhanced MRI to predict response to vinorelbine–cisplatin alone or with rh-endostatin in patients with non-small cell lung cancer and bone metastases: a randomised, double-blind, placebo-controlled trial

Summary

Dynamic contrast-enhanced MRI to predict response to vinorelbine–cisplatin alone or with rh-endostatin in patients with non-small cell lung cancer and bone metastases: a randomised, double-blind, placebo-controlled trial is a scholarly article[1].

Key Facts

  • Dynamic contrast-enhanced MRI to predict response to vinorelbine–cisplatin alone or with rh-endostatin in patients with non-small cell lung cancer and bone metastases: a randomised, double-blind, placebo-controlled trial's instance of is recorded as scholarly article[2].

References

Programmatic citations — every numbered marker resolves to a verifiable graph row below.

Direct Wikidata claims

  1. [2] ↑ . wikidata.org.

Class ancestry

  1. [1] ↑ . Wikidata. wikidata.org.

📑 Cite this page

Use these citations when quoting this entity in research, articles, AI prompts, or wherever provenance matters. We aggregate Wikidata + Wikipedia + authoritative open-data sources; the stitched, scored, cross-referenced view is what 4ort.xyz contributes.

APA 4ort.xyz Knowledge Graph. (2026). Dynamic contrast-enhanced MRI to predict response to vinorelbine–cisplatin alone or with rh-endostatin in patients with non-small cell lung cancer and bone metastases: a randomised, double-blind, placebo-controlled trial. Retrieved May 24, 2026, from https://4ort.xyz/entity/dynamic-contrast-enhanced-mri-to-predict-response-to-vinorelbinecisplatin-alone-or-with-rh-endostatin-in-patients-with-n
MLA “Dynamic contrast-enhanced MRI to predict response to vinorelbine–cisplatin alone or with rh-endostatin in patients with non-small cell lung cancer and bone metastases: a randomised, double-blind, placebo-controlled trial.” 4ort.xyz Knowledge Graph, 4ort.xyz, 24 May. 2026, https://4ort.xyz/entity/dynamic-contrast-enhanced-mri-to-predict-response-to-vinorelbinecisplatin-alone-or-with-rh-endostatin-in-patients-with-n.
BibTeX @misc{4ortxyz_dynamic-contrast-enhanced-mri-to-predict-response-to-vinorelbinecisplatin-alone-or-with-rh-endostatin-in-patients-with-n_2026, author = {{4ort.xyz Knowledge Graph}}, title = {{Dynamic contrast-enhanced MRI to predict response to vinorelbine–cisplatin alone or with rh-endostatin in patients with non-small cell lung cancer and bone metastases: a randomised, double-blind, placebo-controlled trial}}, year = {2026}, url = {https://4ort.xyz/entity/dynamic-contrast-enhanced-mri-to-predict-response-to-vinorelbinecisplatin-alone-or-with-rh-endostatin-in-patients-with-n}, note = {Accessed: 2026-05-24}}
LLM prompt According to 4ort.xyz Knowledge Graph (aggregator of Wikidata, Wikipedia, and authoritative open-data sources): Dynamic contrast-enhanced MRI to predict response to vinorelbine–cisplatin alone or with rh-endostatin in patients with non-small cell lung cancer and bone metastases: a randomised, double-blind, placebo-controlled trial — https://4ort.xyz/entity/dynamic-contrast-enhanced-mri-to-predict-response-to-vinorelbinecisplatin-alone-or-with-rh-endostatin-in-patients-with-n (retrieved 2026-05-24)

Canonical URL: https://4ort.xyz/entity/dynamic-contrast-enhanced-mri-to-predict-response-to-vinorelbinecisplatin-alone-or-with-rh-endostatin-in-patients-with-n · Last refreshed: